Zytiga A New Drug For Prostate Cancer

by admin on September 21, 2011

Zytiga is a trade name of a drug abiraterone acetate which is recently approved drug for the treatment of prostate cancer. Zytiga  in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.  Abiraterone is an inhibitor of CYP17.  Each ZYTIGA tablet contains 250 mg of abiraterone acetate which is given in OD dose.

Zytiga is contraindicated in pregnancy, should be given with caution to hypertensive patients, or patient having electrolyte disturbances. It should be given after meals as its effect increases by 10%.
Zytiga works by cutting off testesterone supply to the cancer cells. This drug can increase the life expectancy of patients by around five months. A trial has been done on around 2000 persons. You can know more about it in the video below

The Story of Abiraterone (Zytiga) from PCF on Vimeo.

For Further Reading :


{ 0 comments… add one now }

Leave a Comment


Previous post:

Next post: